A Phase 1b Study Investigating the Safety, Tolerability and Efficacy of PP353 in the Treatment of Patients With Chronic Low Back Pain Associated With Vertebral Body Endplate Bone Oedema (Modic 1)
Latest Information Update: 06 Mar 2025
At a glance
- Drugs Linezolid (Primary)
- Indications Back pain
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms Modic 1
- Sponsors Persica Pharmaceuticals
- 05 Mar 2025 Primary endpoint has been met. (Change from baseline in Low Back Pain Numerical Rating Scale (LBP NRS) score), according to Persica Pharmaceuticals media release.
- 05 Mar 2025 Results presented in the Persica Pharma Media Release.
- 18 Feb 2025 Status changed from active, no longer recruiting to completed.